Scott Tarriff, CEO at EAGLE PHARMACEUTICALS, INC. (EGRX), sold 39,780 shares at $15.23 ($589K) on 2023-10-02, disclosed to the SEC on 2023-10-04.
Scheduled sale ($589k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.23 | 9,511 | $145K | 24.6% |
| 2 | $15.23 | 9,511 | $145K | 24.6% |
| 3 | $14.41 | 10,024 | $144K | 24.5% |
| 4 | $14.41 | 10,024 | $144K | 24.5% |
| 5 | $15.11 | 710 | $11K | 1.8% |
| Total | $14.81 avg | 39,780 |
| $589K |
| 100% |
| Filing → |
| EGRX | SELL | 2023-05-15 | $1.2M | — | Filing → |
| EGRX | SELL | 2019-04-03 | $2.5M | — | Filing → |
| EGRX | SELL | 2019-03-04 | $1.9M | — | Filing → |